Alnylam Pharmaceuticals (ALNY) Net Margin (2009 - 2026)
Alnylam Pharmaceuticals (ALNY) posted Net Margin of 17.65% for Q1 2026, up 73.57% on a QoQ basis from 10.17% in Q4 2025, and up 2072.0% year-over-year from 0.81% in Q1 2025.
Alnylam Pharmaceuticals (ALNY) Net Margin (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals' Net Margin history runs 18 years deep, the most recent figure standing at 17.65% for Q1 2026.
- Quarterly Net Margin rose 2072.0% year-over-year to 17.65% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 12.69% (up 2250.0% YoY) and the FY2025 annual result came in at 8.45%, up 2082.0% from the prior year.
- Net Margin was 17.65% for Q1 2026 at Alnylam Pharmaceuticals, up from 10.17% in the prior quarter.
- Across five years, Net Margin topped out at 23.43% in Q3 2025 and bottomed at 153.58% in Q3 2022.
- A 5-year average of 36.3% and a median of 14.12% in 2024 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2022 — Net Margin plunged 4458 bps — and 2023, when it surged 17327 bps.
- Alnylam Pharmaceuticals' Net Margin stood at 61.93% in 2022, then surged by 49 bps to 31.35% in 2023, then surged by 55 bps to 14.12% in 2024, then surged by 172 bps to 10.17% in 2025, then soared by 74 bps to 17.65% in 2026.
- Business Quant data shows ALNY's Net Margin at 17.65% in Q1 2026, 10.17% in Q4 2025, and 23.43% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 15.02% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 28.20% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 17.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.65% |
| Dec 31, 2025 | 10.17% |
| Sep 30, 2025 | 23.43% |
| Jun 30, 2025 | -8.57% |
| Mar 31, 2025 | -3.07% |
| Dec 31, 2024 | -14.12% |
| Sep 30, 2024 | -22.27% |
| Jun 30, 2024 | -2.56% |
| Mar 31, 2024 | -13.34% |
| Dec 31, 2023 | -31.35% |
| Sep 30, 2023 | 19.69% |
| Jun 30, 2023 | -86.59% |
| Mar 31, 2023 | -54.53% |
| Dec 31, 2022 | -61.93% |
| Sep 30, 2022 | -153.58% |
| Jun 30, 2022 | -123.39% |
| Mar 31, 2022 | -112.70% |
| Dec 31, 2021 | -99.97% |
| Sep 30, 2021 | -109.00% |
| Jun 30, 2021 | -85.95% |